NCT07240168Active, not recruiting
CurQD as Add-On Therapy in Vedolizumab-Treated Ulcerative Colitis Patients: Retrospective Cohort Study
Drug Retention in Vedolizumab-treated Patients With Active UC After the Addition of Adjunct CurQD: A Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
This study aims to evaluate whether adding CurQD, a nutraceutical composed of Curcumin and QingDai, improves treatment outcomes in patients with active ulcerative colitis (UC) who are already receiving Vedolizumab but still have ongoing disease activity. The study will use de-identified patient records collected through Evinature's global data platform. We will examine whether the addition of CurQD helps patients stay on Vedolizumab longer, improves symptoms and biomarkers, and increases satisfaction with treatment.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 15 Sept 2025
- Start date
- 7 Sept 2025
- Primary completion date
- 20 Aug 2026
- Lead sponsor
- Evinature Ltd.
- Diseases
- Ulcerative colitis
- NCT number
- NCT07240168
What you commit to
- Study type: Observational
- Planned participants: 400
- From 7 Sept 2025 to the primary completion date, 20 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unclear medication status at baseline
Other illness
- Not active disease when starting CurQD
Other
- Vedolizumab for indications other than UC
Who the study is looking for
- Age \>8 years
- Diagnosis of ulcerative colitis (self-reported)
- Completed Evinature clinical assessment between April 1, 2022, and cutoff date
- Vedolizumab treatment at baseline
- Active disease at entry (SCCAI ≥3 or PRO-2 ≥2 with RB ≥1)
- Initiated CurQD at entry
Age in the registry: 8 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Evinature Coordinator of this site? Confirm its status | Binyamina | Israel | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.